Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker
NCT ID: NCT02043821
Last Updated: 2014-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC
NCT02893540
Maintenance Treatment With Capecitabine in Colorectal Cancer Patients
NCT02027363
Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer
NCT02575378
A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer
NCT02717923
Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer
NCT01880658
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days
placebo
14 days
Capecitabine
Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days
Capecitabine
14days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capecitabine
14days
placebo
14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients who achieved objective response or stable disease after 16-24 weeks first line chemotherapy Signed informed consent
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Chao Yang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dong Yan
Beijing Chao Yang Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guangyu An, PhD
Role: STUDY_DIRECTOR
Beijing Chao Yang Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20140116
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.